TP53 and cancer: Yet, the graveyard of wildtype p53 anti-cancer therapeutics is vast, with scientists attributing lack of success to a variety of factors, most often citing the negative crosstalk with mutant p53 where presence of surrounding mutant p53 passed genome instability and mutating ability to targeted cells which allowed them to escape effects of wildtype p53 (Vinyals et al., 1999; Zeimet and Marth, 2003).